How big is P3 Health Partners, Inc.?

As of Jun 18, P3 Health Partners, Inc. has a market capitalization of 45.21 million and reported net sales of 1,485.20 million, with a net profit loss of 305.02 million. The company's balance sheet shows shareholder's funds of 75.94 million and total assets of 783.42 million.

As of Jun 18, P3 Health Partners, Inc. has a market capitalization of 45.21 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 1,485.20 million for the latest four quarters. However, it also experienced a net profit loss of 305.02 million during the same period.<BR><BR>As of Dec 24, the company's balance sheet shows shareholder's funds of 75.94 million and total assets amounting to 783.42 million.

What does P3 Health Partners, Inc. do?

P3 Health Partners, Inc. is a micro-cap company in the miscellaneous industry, reporting net sales of $373 million and a net profit loss of $44 million as of March 2025. Key financial metrics include a market cap of $45.21 million, a debt equity ratio of 2.07, and a return on equity of -509.38%.

Overview:<BR>P3 Health Partners, Inc. operates in the miscellaneous industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 373 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -44 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 45.21 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 2.07 <BR>Return on Equity: -509.38% <BR>Price to Book: 0.71 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold P3 Health Partners, Inc.?

Is P3 Health Partners, Inc. overvalued or undervalued?

As of February 9, 2022, P3 Health Partners, Inc. is considered risky and overvalued due to negative financial metrics and significant underperformance against the S&P 500, with a year-to-date return of -32.68%.

As of 9 February 2022, the valuation grade for P3 Health Partners, Inc. has moved from does not qualify to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 0.75, an EV to EBITDA of -0.81, and a ROE of -509.38%. In comparison, peers like TaskUs, Inc. show a much healthier P/E ratio of 27.32 and EV to EBITDA of 10.15, while Information Services Group, Inc. has a P/E of 22.59 and EV to EBITDA of 12.80, highlighting the stark contrast in financial health.<BR><BR>The stock has underperformed significantly against the S&P 500, with a year-to-date return of -32.68% compared to the benchmark's 12.22%. This underperformance reinforces the notion that P3 Health Partners, Inc. is currently overvalued in the market.

Is P3 Health Partners, Inc. technically bullish or bearish?

As of September 4, 2025, P3 Health Partners, Inc. shows a mildly bullish trend supported by weekly MACD and KST indicators, despite daily moving averages indicating bearishness, while the stock has significantly underperformed the S&P 500 with year-to-date and one-year returns of -32.68% and -67.09%, respectively.

As of 4 September 2025, the technical trend for P3 Health Partners, Inc. has changed from sideways to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, supporting this stance, while the monthly MACD and RSI are bullish. However, the daily moving averages indicate a mildly bearish trend. The Bollinger Bands show a mixed signal with a mildly bullish weekly stance and a bearish monthly view. Overall, the technical indicators suggest a mildly bullish sentiment, albeit with some caution due to the daily moving averages.<BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -32.68% versus the S&P 500's 12.22%, and a one-year return of -67.09% compared to 17.14% for the index.